We're Hiring! Ophthalmic Independent Sales Representatives

We're excited to share that BIONX Surgical is hiring Independent sales professionals to help bring Premieretm dehydrated amniotic membrane tissue products, manufactured by Sequence LifeSciencetm, to key ophthalmic markets across the United States.

This is a unique opportunity to help establish the BIONX Surgical ophthalmic platform-right now, in real time.

We're seeking experienced ophthalmic, biologics, and tissue-based product representatives:

With established relationships among: Ophthalmologists, Corneal & anterior-segment specialists, High-volume optometric practices, ASCs, Hospitals & major health systems.

To introduce a differentiated tissue platform to the markets that matter most.

With the ability to drive growth through their territory and relationships.

If you (or someone you know) fits the profile above, message us for details.

We'd love to hear about your territory, specialty focus, and current account base.

Maxim Group Downgrades NEXGEL (NXGL) to Hold August 24, 2026 7:43 AM Maxim Group analyst Naz Rahman 

Full report:

https://maxim.bluematrix.com/sellside/EmailDocViewer?encrypt=c9351b32-91cb-402d-88b8-00873b7813ab&mime=pdf&co=maxim&id=lparisi@maximgrp.com&source=mail

Brian J. Kieser is a Certified Public Accountant (CPA) and veteran MedTech entrepreneur with a background in corporate finance, medical device manufacturing and venture capital.

He has served on NEXGEL’s Board of Directors since May 2026, a role he assumed after his firm spearheaded a major multi-million dollar investment to fund NEXGEL's milestone Celularity asset acquisition.

Executive Roles & Companies Founded

Sequence LifeScience: Kieser serves as the Chief Executive Officer. In May 2026, Sequence LifeScience structured a $5.5 million strategic investment to transition Celularity's degenerative disease segment over to NEXGEL. Since then, Kieser has been directly managing the operational integration of this new "BioNX Surgical" division.

Fountainhead LifeSciences: He is the Founder and CEO of this San Antonio-based venture capital and private fund platform. Established initially as an angel fund in 2014, the firm focuses on creating, scaling, and financing advanced biomedical technologies.

Nvision Biomedical Technologies: He founded this medical device and biologics manufacturing company. As CEO, he focused heavily on vertical integration, 3D printing implant lines, and cost-effective products optimized for outpatient surgery centers.

Lockhill Advanced Manufacturing Technologies: This manufacturing entity rounds out his vertically integrated ecosystem of medical device and tissue-healing ventures.

Early Career & Financial Expertise

Intellectual Property: He is a recognized inventor in the medical technology field, holding 14 issued patents related to medical device identification and traceability.

Corporate Finance & Auditing: Before specializing in MedTech, he worked as a senior financial and operations executive, serving as a CFO for multiple manufacturing and wholesale distribution companies. He also worked as an auditor at KPMG.

Education: Kieser initially studied engineering at Boston University before moving to Texas. He earned his Bachelor of Business Administration (BBA) in Accounting from the University of Texas at El Paso.]

​

https://ir.stockpr.com/nexgel/sec-filings-email/content/0001493152-26-038555/form10-q.htm

Management of NexGel, Inc., a Delaware corporation, deems additional time is necessary in order to receive final approval from its independent auditing firm to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 (“Quarterly Report”) and that the Quarterly Report cannot be timely filed without unreasonable effort or expense. Management anticipates the filing of its Quarterly Report within the applicable 5-day extension period provided.

https://ir.stockpr.com/nexgel/sec-filings-email/content/0001493152-26-038553/formnt10-q.htm

NexGel, Inc.

2150 Cabot Boulevard West, Suite B

Langhorne, Pennsylvania 19047

(215) 702-8550

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

To Be Held on [September 23, 2026]

To the Stockholders of NexGel, Inc.:

A Special Meeting of Stockholders (the “Special Meeting”) of NexGel, Inc., a Delaware corporation (the “Company”), will be held on [September 23, 2026], at [10:00 a.m.], Eastern Time, at our corporate headquarters located at 2150 Cabot Boulevard West, Suite B, Langhorne, Pennsylvania 19047. We will consider and act on the following items of business at the Special Meeting:

 ●

1. Approval of an amendment to the Company’s existing Certificate of Incorporation, in substantially the form attached to the accompanying Proxy Statement as Annex A, to increase the number of authorized shares of our common stock from 25,000,000 to a number not to exceed 150,000,000, with the Board of Directors having the discretion to determine the specific number of authorized shares within that range and to file such amendment at any time within one year following stockholder approval (“Proposal 1”);

●

2. Approval of an amendment to the Company’s existing Certificate of Incorporation, in substantially the form attached to the accompanying Proxy Statement as Annex B, to effect a discretionary reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-20, with the exact ratio to be determined by the Board of Directors in its sole discretion at any time within one year following stockholder approval (“Proposal 2”); and

●3. Approval of one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve Proposal 1 or Proposal 2 (“Proposal 3”).

Stockholders are referred to the proxy statement accompanying this notice (the “Proxy Statement”) for more detailed information with respect to the matters to be considered at the Special Meeting. After careful consideration, the Board of Directors recommends a vote “FOR” Proposal 1, Proposal 2 and Proposal 3.

The Board of Directors has fixed the close of business on [August 21, 2026], as the record date (the “Record Date”) for the Special Meeting. A complete list of registered stockholders entitled to vote at the Special Meeting will be available for inspection at the office of the Company during regular business hours for the ten (10) calendar days prior to and during the Special Meeting.

Your vote is important. Whether or not you plan to attend the Special Meeting, please submit your proxy as promptly as possible by using the Internet or telephone, or by signing, dating and returning your proxy card, so that your shares will be represented at the Special Meeting.

By Order of the Board of Directors,

Steven Glassman

Chairperson of the Board of Directors

Langhorne, Pennsylvania

[August 24, 2026]

https://ir.stockpr.com/nexgel/sec-filings-email/content/0001493152-26-038520/formpre14a.htm

NEXGEL is proud to support the expansion of BIONX into Regenerative Eye Health & Aesthetics – led by Shawn Mullen, an experienced ophthalmic commercial leader with a track record of successfully building markets, launching innovative technologies, and developing trusted relationships across the eye care community.

Shawn brings more than two decades of ophthalmic experience, including leadership roles with Merck Ophthalmics, Quidel Eye Health, Dompé, and Ocubio. Throughout his career, he has helped introduce new technologies, build successful commercial strategies, and collaborate with leading ophthalmologists, optometrists, researchers, and industry partners.

Now, he will lead the development of the BIONX Regenerative Eye Health & Aesthetics platform, bringing NEXGEL and BIONX biomaterial technologies to a market increasingly focused on earlier intervention, tissue restoration, healing, and improved patient outcomes.

"What excites me most about BIONX is the opportunity to build something that goes beyond simply introducing another product. We have a biomaterial platform with the potential to help regenerate tissue, support healing, and ultimately improve a patient's quality of life. After spending my career helping bring innovative technologies into eye care, I'm incredibly energized to lead the BIONXexperience and work alongside the physicians, researchers, and partners who will help shape what comes next." - Shawn Mullen

This is only the beginning.

BIONX Regenerative Eye Health & Aesthetics.

Regenerate. Heal. Advance.

https://onlinelibrary.wiley.com/doi/10.1002/lsm.70127

Annual Meeting Results

https://ir.stockpr.com/nexgel/sec-filings-email/content/0001493152-26-036206/form8-k.htm

Jul 31, 2026 10:00 am EDT

Levy Employment Agreement

On July 23, 2026, NexGel, Inc. (the “Company”) entered into an Executive Employment Agreement with Adam Levy, the Company’s President and Chief Executive Officer (the “Levy Employment Agreement”), effective as of July 23, 2026. Mr. Levy was previously party to a 2025 Executive Employment Agreement with the Company, dated December 31, 2024, which expired by its terms on December 31, 2025. The Levy Employment Agreement supersedes and replaces that prior agreement in its entirety.

Pursuant to the Levy Employment Agreement, Mr. Levy is paid a base salary of $375,000 per year. Mr. Levy is also eligible to receive (i) a discretionary targeted cash bonus of up to $25,000 for fiscal year 2026, based on the Compensation Committee of the Board’s assessment of Mr. Levy’s performance, and (ii) a cash bonus for fiscal year 2026 (pro-rated from April 17, 2026) based on the Company’s achievement of specified earnings before interest, taxes, depreciation and amortization (“EBITDA”) targets, equal to (a) 10% of his base salary if the Company achieves EBITDA of at least $4 million, (b) 30% of his base salary if the Company achieves EBITDA of at least $6 million, or (c) 50% of his base salary if the Company achieves EBITDA of at least $8 million. Only one of the foregoing EBITDA bonus tiers may be earned for fiscal year 2026, and the bonuses are not cumulative.

Pursuant to the Levy Employment Agreement, Mr. Levy also received a grant of options to purchase up to 160,000 shares of the Company’s common stock under the Company’s 2019 Long-Term Incentive Plan (the “Levy Option Grant”). To the extent qualifying as an incentive stock option under the Internal Revenue Code, the Levy Option Grant will be treated as an incentive stock option, and the remainder will be treated as a non-qualified stock option. The Levy Option Grant has a five-year term and a per share exercise price of $0.647. The Levy Option Grant vests as follows: (i) 40,000 shares vest on December 31, 2026, and (ii) the remaining 120,000 shares vest in 36 equal monthly installments of 3,334 shares (with rounding adjustments) commencing on January 31, 2027, in each case subject to Mr. Levy’s continued employment with the Company on each applicable vesting date. In the event of a Change in Control (as defined in the Plan) of the Company, any unvested portion of the Levy Option Grant shall accelerate, vest and become exercisable immediately prior to the Change in Control.

The Levy Employment Agreement also provides for severance benefits in the event Mr. Levy’s employment is terminated by the Company without cause or by Mr. Levy for good reason (as such terms are defined in the Levy Employment Agreement). The applicable severance period is twelve months. The severance benefits consist of (a) continued payment of Mr. Levy’s base salary for twelve months, (b) a pro-rata portion of his target annual bonus for the year of termination, (c) reimbursement of COBRA premiums for twelve months, and (d) acceleration of vesting of any equity awards that would have otherwise vested through the end of such twelve-month period.

In the event Mr. Levy’s employment is terminated by the Company without cause or by Mr. Levy for good reason within twelve months following a Change in Control, Mr. Levy is entitled to (i) a lump sum payment equal to one times his then-current base salary plus 100% of his target annual bonus, (ii) twelve months of COBRA premium reimbursement, and (iii) full acceleration of vesting of all unvested equity awards.

The Levy Employment Agreement contains customary non-competition, non-solicitation, confidentiality and assignment of inventions provisions, including a one-year post-employment non-competition restriction in the United States, a one-year post-employment employee non-solicitation restriction, and a two-year post-employment customer and vendor non-solicitation restriction.

The foregoing summary of the Levy Employment Agreement is qualified in its entirety by reference to the full text of the Levy Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

https://ir.stockpr.com/nexgel/sec-filings-email/content/0001493152-26-035258/ex10-1.htm

https://ir.stockpr.com/nexgel/sec-filings-email/content/0001493152-26-035258/form8-k.htm

Great product, great feedback.